Wai Chun Bio-Technology Limited provided consolidated earnings guidance for the year ended December 31, 2021. For the year, the company expects unaudited consolidated management accounts of the Group and the information currently available to the Board for the twelve months ended 31 December 2021 (the "Management Accounts"), the Group is expected to record a loss of not less than HKD 10,000,000.00 for the twelve months ended 31 December 2021. The loss was primarily due to the decrease in sales because of relapse of Covid-19 in Mainland China in the second half year of 2021 and the increase in finance costs which was caused by the increase in interest expenses of convertible bonds.